[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589251":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":50,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":66,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Group Assignment",null,"Each subject receive a single intravenous injection of 11C\u002F18F-HED and undergo PET\u002FCT or MRI imaging within the specificed time.",[13],"Diagnostic Test: 11C\u002F18F-HED",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","11C\u002F18F-HED",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Haonan Yu, MD","CONTACT","+8613821000597","dreamadam@126.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Qiusong Chen, MD","+862260362190","qs_c8@hotmail.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tianjin Medical University General Hospital","RECRUITING","Tianjin","Tianjin Municipality","300052","China","CN",{"type":39,"coordinates":40},"Point",[41,42],117.17667,39.14222,{"lat":42,"lon":41},[45],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Shaobo Yao, PhD","Prof.",[51],{"name":31,"class":6},"100589251","hydroxyephedrine-petct-in-sympathetic-nervous-system-disease-100589251",false,"NCT06951984","Hydroxyephedrine PET\u002FCT in Sympathetic Nervous System Disease","Hydroxyephedrine PET\u002FCT in Sympathetic Nervous System Diseases","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled HED PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":64,"type":65},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 11C\u002F18F-HED positron emission tomography\u002F computed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[70,71,72],"Sympathetic Nervous System Diseases","Sympathetic Nervous Structure Injury","Sympathetic Nerve Injury",[74,75,76],"PET\u002FCT","MRI","Hydroxyephedrine","2025-04-23",{"date":79,"type":80},"2025-04-30","ACTUAL",{"date":82,"type":80},"2013-03-01",{"date":84,"type":65},"2028-03-01",{"name":5,"class":6},1]